{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:59:45Z","timestamp":1785196785712,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,10]],"date-time":"2027-06-10T00:00:00Z","timestamp":1812585600000},"content-version":"am","delay-in-days":344,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["2K24DA042720"],"award-info":[{"award-number":["2K24DA042720"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["K12HS026383"],"award-info":[{"award-number":["K12HS026383"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.japh.2026.103130","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:28:35Z","timestamp":1778023715000},"page":"103130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Qualitative study of blister pack use during buprenorphine low dose initiation"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6215-6362","authenticated-orcid":false,"given":"Jacqueline","family":"Parizher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmi","family":"Panigrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8473-4903","authenticated-orcid":false,"given":"Michelle","family":"Geier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine S.","family":"Soran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8120-3824","authenticated-orcid":false,"given":"Hannah R.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5838-8592","authenticated-orcid":false,"given":"Kelly R.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip O.","family":"Coffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4786-356X","authenticated-orcid":false,"given":"Leslie W.","family":"Suen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2S Suppl 1","key":"10.1016\/j.japh.2026.103130_bib1","first-page":"1","article-title":"The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update","volume":"14","year":"2020","journal-title":"J Addict Med"},{"issue":"9","key":"10.1016\/j.japh.2026.103130_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.35895","article-title":"Buprenorphine-precipitated withdrawal among hospitalized patients using fentanyl","volume":"7","author":"Thakrar","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.japh.2026.103130_bib3","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/dar.13394","article-title":"Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: a case series","volume":"41","author":"Shearer","year":"2022","journal-title":"Drug Alcohol Rev"},{"issue":"5","key":"10.1016\/j.japh.2026.103130_bib4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40261-021-01032-7","article-title":"The pharmacology of buprenorphine microinduction for opioid use disorder","volume":"41","author":"De Aquino","year":"2021","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.japh.2026.103130_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108147","article-title":"Protracted renal clearance of fentanyl in persons with opioid use disorder","volume":"214","author":"Huhn","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.japh.2026.103130_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/ADM.0000000000000952","article-title":"A Plea from people who use drugs to clinicians: new ways to initiate buprenorphine are urgently needed in the fentanyl era","volume":"16","author":"Sue","year":"2022","journal-title":"J Addict Med"},{"issue":"6","key":"10.1016\/j.japh.2026.103130_bib7","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/ADM.0000000000001202","article-title":"ASAM clinical considerations: buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids","volume":"17","author":"Weimer","year":"2023","journal-title":"J Addict Med"},{"issue":"1","key":"10.1016\/j.japh.2026.103130_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.56253","article-title":"Outpatient low-dose initiation of buprenorphine for people using fentanyl","volume":"8","author":"Suen","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.japh.2026.103130_bib9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/ajad.13135","article-title":"Microinduction of buprenorphine\/naloxone: a review of the literature","volume":"30","author":"Ahmed","year":"2021","journal-title":"Am J Addict"},{"issue":"4","key":"10.1016\/j.japh.2026.103130_bib10","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1097\/ADM.0000000000001154","article-title":"The Howard Street Method: a community pharmacy-led low dose overlap buprenorphine initiation protocol for individuals using fentanyl","volume":"17","author":"Noel","year":"2023","journal-title":"J Addict Med"},{"issue":"5","key":"10.1016\/j.japh.2026.103130_bib11","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/ADM.0000000000000961","article-title":"Rapid overlap initiation protocol using low dose buprenorphine for opioid use disorder treatment in an outpatient setting: a case series","volume":"16","author":"Suen","year":"2022","journal-title":"J Addict Med"},{"issue":"11","key":"10.1016\/j.japh.2026.103130_bib13","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1111\/add.16600","article-title":"Dose-specific clinical outcomes in patients with opioid use disorder treated with 24-32 mg\/day of buprenorphine","volume":"119","author":"D'Agata Mount","year":"2024","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.japh.2026.103130_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12954-024-00998-9","article-title":"Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study","volume":"21","author":"Jones","year":"2024","journal-title":"Harm Reduct J"},{"issue":"7","key":"10.1016\/j.japh.2026.103130_bib15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40261-021-01048-z","article-title":"Blister-packing of 2 mg buprenorphine monoproduct as a patient-centered method of microdosing for buprenorphine induction","volume":"41","author":"Accurso","year":"2021","journal-title":"Clin Drug Investig"},{"issue":"5","key":"10.1016\/j.japh.2026.103130_bib16","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/PRA.0000000000000252","article-title":"Blister packaging medication increases treatment adherence in psychiatric patients","volume":"23","author":"Gutierrez","year":"2017","journal-title":"J Psychiatr Pract"},{"issue":"18","key":"10.1016\/j.japh.2026.103130_bib17","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/ajhp\/zxab193","article-title":"Impact on patients' compliance with medication using prepacked blisters for multidrug medical therapy: I-COMPLY study","volume":"78","author":"Shah","year":"2021","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"10.1016\/j.japh.2026.103130_bib18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.9740\/mhc.2025.06.176","article-title":"Evaluating the efficacy of blister packaging in improving medication adherence within psychiatry: a systematic literature review","volume":"15","author":"Borrelli","year":"2025","journal-title":"Ment Health Clin"},{"key":"10.1016\/j.japh.2026.103130_bib19","article-title":"\"It's like scratching at the door\": experiences of outpatient buprenorphine low dose initiation among people using fentanyl","volume":"184","author":"Suen","year":"2026","journal-title":"J Subst Use Addict Treat"},{"key":"10.1016\/j.japh.2026.103130_bib20","series-title":"Epic [Electronic Health Record Software]","year":"2024"},{"issue":"7","key":"10.1016\/j.japh.2026.103130_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.17128","article-title":"High-dose buprenorphine induction in the emergency department for treatment of opioid use disorder","volume":"4","author":"Herring","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.japh.2026.103130_bib22","author":"Thadani"},{"issue":"2","key":"10.1016\/j.japh.2026.103130_bib23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jac5.1915","article-title":"Evaluating a novel pharmacist-led buprenorphine outreach service for treatment of opioid use disorder in individuals residing in supportive housing","volume":"7","author":"Ly","year":"2024","journal-title":"J Am Coll Clin Pharm"},{"issue":"6","key":"10.1016\/j.japh.2026.103130_bib24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s40271-016-0178-8","article-title":"A case study investigation into the use of multi-compartment compliance aids in older people resident in very sheltered housing","volume":"9","author":"MacLure","year":"2016","journal-title":"Patient"},{"issue":"5","key":"10.1016\/j.japh.2026.103130_bib25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/11587180-000000000-00000","article-title":"How do the attitudes and beliefs of older people and healthcare professionals impact on the use of multi-compartment compliance aids?: A qualitative study using grounded theory","volume":"28","author":"Nunney","year":"2011","journal-title":"Drugs Aging"},{"issue":"2","key":"10.1016\/j.japh.2026.103130_bib26","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s11096-017-0580-x","article-title":"The experiences and beliefs of older people in Scottish very sheltered housing about using multi-compartment compliance aids","volume":"40","author":"Stewart","year":"2018","journal-title":"Int J Clin Pharm"},{"issue":"7","key":"10.1016\/j.japh.2026.103130_bib27","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/add.15353","article-title":"Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network","volume":"116","author":"Wu","year":"2021","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.japh.2026.103130_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/ADM.0000000000000555","article-title":"Defining low-threshold buprenorphine treatment","volume":"14","author":"Jakubowski","year":"2020","journal-title":"J Addict Med"},{"issue":"5","key":"10.1016\/j.japh.2026.103130_bib29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/ajad.12925","article-title":"Brief report: low-barrier buprenorphine initiation predicts treatment retention among latinx and non-latinx primary care patients","volume":"28","author":"Lee","year":"2019","journal-title":"Am J Addict"},{"issue":"10","key":"10.1016\/j.japh.2026.103130_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.36914","article-title":"Telemedicine buprenorphine initiation and retention in opioid use disorder treatment for Medicaid enrollees","volume":"6","author":"Hammerslag","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.japh.2026.103130_bib33","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13722-024-00519-w","article-title":"Pharmacy-based preventive services for opioid use disorder: a survey of U.S. pharmacists","volume":"19","author":"Wu","year":"2024","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"10.1016\/j.japh.2026.103130_bib34","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s11096-018-0749-y","article-title":"Patients' experiences with multidose drug dispensing: a cross sectional study","volume":"41","author":"Mertens","year":"2019","journal-title":"Int J Clin Pharm"},{"issue":"583","key":"10.1016\/j.japh.2026.103130_bib35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3399\/bjgp11X556191","article-title":"Medication compliance aids: a qualitative study of users' views","volume":"61","author":"Lecouturier","year":"2011","journal-title":"Br J Gen Pract"},{"issue":"8","key":"10.1016\/j.japh.2026.103130_bib36","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.27016","article-title":"Injectable-only overlapping buprenorphine starting protocol in a low-threshold setting","volume":"8","author":"Waters","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.japh.2026.103130_bib37","article-title":"Extended-release 7-day injectable buprenorphine for patients with minimal to mild opioid withdrawal","volume":"7","author":"D'Onofrio","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.japh.2026.103130_bib38","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1177\/29767342251330412","article-title":"Outpatient initiation of 7-day injectable buprenorphine: a direct-to-inject case series","volume":"46","author":"Rosenwohl-Mack","year":"2025","journal-title":"Subst Use Addctn J"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319126001159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319126001159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:31:37Z","timestamp":1785195097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319126001159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1544319126001159"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2026.103130","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Qualitative study of blister pack use during buprenorphine low dose initiation","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2026.103130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103130"}}